Stock Taper 
Evolus, Inc. is a performance beauty company based in Newport Beach, California, offering medical aesthetic products like Jeuveau, a botulinum toxin for temporary wrinkle reduction in adults.
Evolysse, launched in April 2025, is a hyaluronic acid dermal filler for moderate to severe facial wrinkles, expanding Evolus’s portfolio alongside Jeuveau as part of its growth strategy.
In its second-quarter 2025 earnings report, Evolus significantly lowered its full-year revenue guidance from a range of $345-$355 million to $295-$305 million. This downward revision was attributed to a slowdown in the U.S. aesthetic market and decreased consumer sentiment, leading to a sharp sell-off in the company's stock.
In a pivotal strategic shift, Evolus launched its second major product line, the Evolysse™ collection of hyaluronic acid (HA) injectable gels, in 2025. This move transitions the company from a single-product entity, primarily reliant on its neurotoxin Jeuveau®, to a broader 'performance beauty' company with a more diversified portfolio in the competitive aesthetics market.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The U.S. Food and Drug Administration's Office of Prescription Drug Promotion in September issued a warning letter to Evolus Inc. (NASDAQ:EOLS) regarding misleading Instagram promotional posts for its injectable prescription drug, Jeuveau (prabotulinumtoxinA-xvfs).
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic practices, providers, and patients to support organizations and causes that positively impact their communities. The first Wings by Evolus initiative will launch in October in recognition of Breast Cancer Awareness M.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 CBLL | $24.57 | COMPARE |
 SLDB | $6.92 | COMPARE |
 KIDS | $22.82 | COMPARE |
 AUTL | $1.80 | COMPARE |
 KMDA | $8.16 | COMPARE |
 NGNE | $25.74 | COMPARE |
 TMCI | $4.18 | COMPARE |
 QSI | $1.25 | COMPARE |
